Figure 3.

The increased expression of SRXN1 in patients with prostate cancer (PCa) is associated with high-risk/worse prognosis and lower disease-/progression-free survival. (a) The level of SRXN1 gene expression (median) in PCa patients with low-risk/better prognosis (green) and patients with high-risk/worse prognosis (red). Data and analyses were cataloged using the SurvExpress database [52] from a MSKCC study [18]. The difference between boxplots is statistically significant with p = 3.03⁻³². (b) Kaplan-Meier curve displaying disease-/progression-free survival of PCa patients with (red) or without (blue) SRXN1 alterations, cataloged using the cBioPortal human database [49, 50] from a provisional study of TCGA (https://cancergenome.nih.gov/). Curves are significantly different with p = 2.104⁻⁴.